Table 3 |
|||
|
Numbers of study subjects receiving potentially inappropriate medications for treatment of GAD* |
|||
|
Medication |
Potentially Inappropriate |
Possibly Appropriate |
Total |
|
|
|||
|
Benzodiazepines |
|||
|
Short-acting |
|||
|
Alprazolam1 |
0 (0.0) |
29 (3.0) |
29 (3.0) |
|
Lorazepam2 |
50 (5.1) |
21 (2.2) |
71 (7.3) |
|
Lormetazepam |
14 (1.4) |
0 (0.0) |
14 (1.4) |
|
Oxazepam3 |
0 (0.0) |
88 (9.0) |
88 (9.0) |
|
Temazepam4 |
8 (0.8) |
0 (0.0) |
8 (0.8) |
|
Tetrazepam |
0 (0.0) |
29 (3.0) |
29 (3.0) |
|
Triazolam5 |
0 (0.0) |
1 (0.1) |
1 (0.1) |
|
Zolpidem6 |
32 (3.3) |
3 (0.3) |
34 (3.5) |
|
Any of above |
97 (9.9) |
162 (16.6) |
242 (24.8) |
|
Long-acting** |
|||
|
Chlordiazepoxide |
6 (0.6) |
--- |
6 (0.6) |
|
Chlorazepate |
11 (1.1) |
--- |
11 (1.1) |
|
Clobazam |
2 (0.2) |
--- |
2 (0.2) |
|
Clonazepam |
3 (0.3) |
--- |
3 (0.3) |
|
Diazepam |
91 (9.3) |
--- |
91 (9.3) |
|
Flunitrazepam |
7 (0.7) |
--- |
7 (0.7) |
|
Flurazepam |
6 (0.6) |
--- |
6 (0.6) |
|
Halazepam |
0 (0.0) |
--- |
0 (0.0) |
|
Medazepam |
5 (0.5) |
--- |
5 (0.5) |
|
Nordazepam |
2 (0.2) |
--- |
2 (0.2) |
|
Prezepam |
0 (0.0) |
--- |
0 (0.0) |
|
Bromazepam |
93 (9.5) |
--- |
93 (9.5) |
|
Nitrazepam |
14 (1.4) |
--- |
14 (1.4) |
|
Midazolam |
0 (0.0) |
--- |
0 (0.0) |
|
Any of above |
225 (23.1) |
--- |
225 (23.1) |
|
Any of above |
298 (30.6) |
162 (16.6) |
426 (43.7) |
|
Tricyclic antidepressants |
|||
|
Amitriptyline |
52 (5.3) |
--- |
52 (5.3) |
|
Amitriptylinoxide |
0 (0.0) |
3 (0.3) |
3 (0.3) |
|
Clomipramine |
0 (0.0) |
4 (0.4) |
4 (0.4) |
|
Dibenzepin |
0 (0.0) |
3 (0.3) |
3 (0.3) |
|
Desipramine |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Doxepin |
70 (7.2) |
--- |
70 (7.2) |
|
Imipramine |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Maprotiline |
0 (0.0) |
4 (0.4) |
4 (0.4) |
|
Nortriptyline |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Opipramol |
0 (0.0) |
105 (10.8) |
105 (10.8) |
|
Trimipramine |
0 (0.0) |
29 (3.0) |
29 (3.0) |
|
Any of above |
119 (12.2) |
142 (14.6) |
250 (25.6) |
|
Selective serotonin reuptake inhibitors |
|||
|
Escitalopram |
0 (0.0) |
7 (0.7) |
7 (0.7) |
|
Citalopram |
0 (0.0) |
40 (4.1) |
40 (4.1) |
|
Fluoxetine |
11 (1.1) |
0 (0.0) |
11 (1.1) |
|
Fluvoxamine |
0 (0.0) |
3 (0.3) |
3 (0.3) |
|
Paroxetine |
0 (0.0) |
16 (1.6) |
16 (1.6) |
|
Sertraline |
0 (0.0) |
13 (1.3) |
13 (1.3) |
|
Any of above |
11 (1.1) |
77 (7.9) |
86 (8.8) |
|
Venlafaxine |
0 (0.0) |
9 (0.9) |
9 (0.9) |
|
Hydroxyzine |
4 (0.4) |
--- |
4 (0.4) |
|
Buspirone |
0 (0.0) |
5 (0.5) |
5 (0.5) |
|
Pregabalin |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Trifluoperazine |
0 (0.0) |
0 (0.0) |
0 (0.0) |
|
Any of above |
392 (40.2) |
345 (35.4) |
607 (62.3) |
|
|
|||
|
*All values are number of patients (%); dose calculated using all values found in database **Any use of long-acting benzodiazepines deemed potentially inappropriate 1Dose >2 mg/d deemed potentially inappropriate 2Dose >3 mg/d deemed potentially inappropriate 3Dose >60 mg/d deemed potentially inappropriate 4Dose >15 mg/d deemed potentially inappropriate 5Dose > 0.25 mg/d deemed potentially inappropriate 6Dose >5 mg/d deemed potentially inappropriate GAD: Generalized anxiety disorder |
|||
|
Berger et al. BMC Geriatrics 2009 9:31 doi:10.1186/1471-2318-9-31 |
|||
